| Autor: |
Migden M; Department of Dermatology, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Head and Neck Surgery, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas., Loquai C; Department of Dermatology, University Medical Center Mainz, Mainz, Germany., Robert C; Department of Dermatology, Institut Gustave Roussy and Paris-Saclay University, Villejuif, France., Baurain JF; Department of Medical Oncology, Institut Roi Albert II, Cliniques universitaires Saint-Luc, UCLouvain, Brussels, Belgium.; Institute for Experimental and Clinical Research, Université catholique de Louvain, Brussels, Belgium., Squittieri N; Medical Affairs Oncology, Sun Pharmaceutical Industries, Inc, Princeton, New Jersey., Arntz R; Sun Pharmaceutical Industries, (Europe) B.V., Hoofddorp, North Holland, the Netherlands., Dierlamm J; Sun Pharmaceutical Industries, (Europe) B.V., Hoofddorp, North Holland, the Netherlands., Dréno B; Department of Dermatology, University Hospital Nantes, Nantes, France. |
| Abstrakt: |
Competing Interests: Migden has participated on advisory boards and received honoraria from Genentech; Novartis; Sun Pharmaceutical Industries, Inc; and Regeneron. Loquai acted as a speaker for, participated in an advisory board for, and received honoraria from Bristol-Myers Squibb, Roche, Novartis, and Merck Sharp & Dohme. Robert has received consulting fees from Amgen, Array BioPharma, Bristol-Myers Squibb, Merck, Merck-Serono, Novartis, Pierre-Fabre, and Roche. Baurain reports that his institution has received fees for advisory boards from Bristol-Myer Squibb, Novartis, Pierre-Fabre, Sun Pharmaceutical, Sanofi-Regeneron, Amgen, Merck-Serono, and Merck Sharp & Dohme. Squittieri is an employee of Sun Pharmaceutical Industries, Inc. Arntz and Dierlamm are employees of Sun Pharmaceutical Industries, (Europe) B.V. Dréno has been a consultant or advisor for Bristol-Myers Squibb, GlaxoSmithKline, Roche, and Novartis; has served on speakers’ bureaus for Bristol-Myers Squibb, GlaxoSmithKline, and Roche. |
